KRAS and colorectal carcinoma: Some investigators have reported that drugs that target signalling pathways involved in tumourigenesis; for example, cetuximab for wild-type K-ras CRC [6], and bevacizumab for CRC [7], improve survival of patients with CRC over chemotherapy alone [6–8].